Clinical trial / 2020
In the VITAL trial, vitamin D3 supplementation did not reduce total cancer incidence or major CVD events, but showed a signal for reduced cancer mortality.
The VITAL trial evaluated daily vitamin D3 (2000 IU) and marine omega-3 fatty acids (1 g) over a median of 5.3 years in 25,871 older U.S. adults. Vitamin D did not significantly reduce total invasive cancer incidence (HR = 0.96 [95% CI 0.88-1.06]), major CVD events (HR = 0.97 [0.85-1.12]), or all-cause mortality (HR = 0.99 [0.87-1.12]). However, it showed a signal for reduced total cancer mortality (HR = 0.83 [0.67-1.02]), which was significant when excluding the first year (HR = 0.79 [0.63-0.99]) or first 2 years (HR = 0.75 [0.59-0.96]) of follow-up. Updated meta-analyses including VITAL and other trials indicated a significant reduction in cancer mortality, but not cancer incidence or CVD endpoints.
- Study type
- Randomized, placebo-controlled, 2x2 factorial trial and meta-analyses
- Who was studied
- 25,871 U.S. men aged >=50 and women aged >=55, including 5,106 African Americans
- What was measured
- Total invasive cancer incidence, major cardiovascular disease events, cancer mortality, and all-cause mortality
THE PAPER
Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials.
Manson JE, Bassuk SS, Buring JE, VITAL Research Group. J Steroid Biochem Mol Biol, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.